Champions Oncology, Inc. (CSBR)

Price$5.84

Value ScoreC

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-30.75%

Price vs S&P 500 (4W)-7.56%

VGM Score47.20

Market Capitalization$81.03M

P/E Ratio (Annual)17.24x

All Metrics

P/CF (Annual)10.97x

Book Value / Share (Quarterly)$0.31

P/TBV (Annual)17.39x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.06%

Cash Flow / Share (Quarterly)$0.27

Price vs S&P 500 (YTD)-26.29%

Gross Margin (TTM)45.88%

Net Profit Margin (TTM)-3.94%

EPS (TTM)$-0.17

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$-0.17

Revenue Growth (5Y)12.13%

EPS (Annual)$0.33

ROI (Annual)117.76%

Gross Margin (Annual)50.15%

Net Profit Margin (5Y Avg)-2.83%

Cash / Share (Quarterly)$0.51

P/E Basic Excl Extra (TTM)32.38x

Revenue Growth QoQ (YoY)-2.82%

P/E Normalized (Annual)17.24x

ROA (Last FY)14.53%

Revenue Growth TTM (YoY)-1.10%

EBITD / Share (TTM)$-0.08

ROE (5Y Avg)-3.36%

Operating Margin (TTM)-4.53%

Cash Flow / Share (Annual)$0.51

P/B Ratio18.92x

P/B Ratio (Quarterly)23.12x

Net Income / Employee (Annual)$22,100

EV / Revenue (TTM)1.28x

Net Interest Coverage (TTM)-6.62x

ROA (TTM)-7.51%

EPS Growth QoQ (YoY)-64.35%

EV / EBITDA (TTM)20.24x

EPS Incl Extra (Annual)$0.33

Current Ratio (Annual)0.94x

Quick Ratio (Quarterly)0.93x

3-Month Avg Trading Volume0.01M

52-Week Price Return-2.42%

EV / Free Cash Flow (Annual)10.58x

P/E Incl Extra (TTM)32.38x

Revenue / Employee (TTM)$272,000

Tangible BV / Share (Quarterly)$0.70

P/S Ratio (Annual)1.42x

Asset Turnover (Annual)1.76x

52-Week High$9.63

Operating Margin (5Y Avg)-2.86%

EPS Excl Extra (Annual)$0.33

CapEx CAGR (5Y)-29.41%

26-Week Price Return-14.82%

Quick Ratio (Annual)0.88x

13-Week Price Return-2.59%

Total Debt / Equity (Annual)0.06x

Current Ratio (Quarterly)0.98x

Enterprise Value$74.01M

Revenue / Share Growth (5Y)8.03%

Asset Turnover (TTM)1.91x

Book Value / Share Growth (5Y)7.27%

Revenue / Employee (Annual)$267,300

Inventory Turnover (Annual)50.00x

Pretax Margin (Annual)8.12%

Cash / Share (Annual)$0.71

3-Month Return Std Dev42.55%

Gross Margin (5Y Avg)47.26%

Net Income / Employee (TTM)$-10,700

EBITDA Interim CAGR (5Y)-44.90%

ROE (Last FY)124.63%

Net Interest Coverage (Annual)-2.54x

EPS Basic Excl Extra (Annual)$0.33

P/FCF (TTM)10.64x

Receivables Turnover (TTM)4.16x

EV / Free Cash Flow (TTM)19.39x

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-0.17

Receivables Turnover (Annual)5.49x

ROI (TTM)-55.72%

P/S Ratio (TTM)1.40x

Pretax Margin (5Y Avg)-2.80%

Revenue / Share (Annual)$3.99

Tangible BV / Share (Annual)$0.70

Forward P/E48.63x

Free OCF CAGR (5Y)58.93%

Price vs S&P 500 (52W)-30.63%

P/E Ratio (TTM)32.38x

Year-to-Date Return-15.56%

5-Day Price Return-2.91%

EPS Normalized (Annual)$0.33

ROA (5Y Avg)-5.20%

Net Profit Margin (Annual)8.26%

Month-to-Date Return-2.10%

Cash Flow / Share (TTM)$-0.32

EBITD / Share (Annual)$0.43

EPS Growth (3Y)104.02%

Operating Margin (Annual)8.00%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)18.44x

ROI (5Y Avg)-4.55%

P/E Excl Extra (TTM)32.38x

LT Debt / Equity (Quarterly)0.02x

EPS Basic Excl Extra (TTM)$-0.17

P/TBV (Quarterly)17.39x

P/B Ratio (Annual)26.21x

Inventory Turnover (TTM)50.40x

Pretax Margin (TTM)-4.14%

Book Value / Share (Annual)$0.27

Price vs S&P 500 (13W)-12.33%

Beta0.37x

P/FCF (Annual)11.58x

Revenue / Share (TTM)$4.17

ROE (TTM)-58.02%

52-Week Low$5.50

vGradeC

gGradeC

mGradeC

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
CSBRChampions Oncology, Inc.	C	C	C	$5.84
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

Champions Oncology provides precision medicine technology for oncology drug development and personalized cancer treatment. Its Personalized Oncology Solutions segment delivers tumor-specific genomic data to physicians for treatment customization, while its Translational Oncology Solutions segment supports pharmaceutical companies with tumor specimens and research services for drug development. The company generates revenue primarily through research services to both healthcare providers and biopharma clients.